← All trials
NCT03156439
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 22, 2017
- Primary completion
- Aug 11, 2017
- Completion date
- Aug 18, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 8
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Biscayne Neurotherapeutics, Inc.Lead sponsor
- Melbourne HealthCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.